Decoy Therapeutics (DCOY) Other Non-Current Assets (2014 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Other Non-Current Assets of $29882.0 for Q1 2026, down 12.9% year-over-year from $34306.0 in Q1 2025, and down 3.57% quarter-over-quarter from $30988.0 in Q4 2025.
Decoy Therapeutics (DCOY) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Other Non-Current Assets for 13 consecutive years, with $29882.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 12.9% year-over-year to $29882.0; the TTM figure through Mar 2026 stood at $29882.0 (down 12.9% YoY), while the FY2025 annual figure was $30988.0, down 12.49% from the prior year.
- Other Non-Current Assets fell to $29882.0 in Q1 2026 per DCOY's latest filing, from $30988.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $170907.0 in Q1 2022 and bottomed at $29882.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $76306.1 across 5 years, with a median of $53390.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets sank 59.69% — and 2025, when it declined 12.11%.
- Decoy Therapeutics' Other Non-Current Assets stood at $130501.0 in 2022, then plunged by 48.77% to $66850.0 in 2023, then tumbled by 47.03% to $35412.0 in 2024, then declined by 12.49% to $30988.0 in 2025, then retreated by 3.57% to $29882.0 in 2026.
- Business Quant data shows DCOY's Other Non-Current Assets at $29882.0 in Q1 2026, $30988.0 in Q4 2025, and $32094.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | 28,775.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28,775.00 |
| Mar 31, 2026 | 29,882.00 |
| Dec 31, 2025 | 30,988.00 |
| Sep 30, 2025 | 32,094.00 |
| Jun 30, 2025 | 33,200.00 |
| Mar 31, 2025 | 34,306.00 |
| Dec 31, 2024 | 35,412.00 |
| Sep 30, 2024 | 36,518.00 |
| Jun 30, 2024 | 39,931.00 |
| Mar 31, 2024 | 53,390.00 |
| Dec 31, 2023 | 66,850.00 |
| Sep 30, 2023 | 80,444.00 |
| Jun 30, 2023 | 99,048.00 |
| Mar 31, 2023 | 114,852.00 |
| Dec 31, 2022 | 130,501.00 |
| Sep 30, 2022 | 146,461.00 |
| Jun 30, 2022 | 162,419.00 |
| Mar 31, 2022 | 170,907.00 |
| Dec 31, 2021 | 193,874.00 |
| Sep 30, 2021 | 201,389.00 |